Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Alzheimer’s advocates laud the approval of Aduhelm, but experts raise questions about its effectiveness and cost.
The Epclusa and Mavyret combination pills are now indicated for kids as young as age 3.
Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.
The Pfizer-BioNTech vaccine was 100% effective in a study of adolescents; trials for younger children are now underway.
The Johnson & Johnson vaccine, which is easier to store and deliver, will help speed up the coronavirus vaccine rollout.
Bamlanivimab and etesevimab may be given to people with mild to moderate COVID-19 who are at high risk for progression to severe disease.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
Moderna’s coronavirus vaccine is 94% effective in preventing symptomatic COVID-19—and it may also reduce asymptomatic infection.
The test is authorized for individuals two years of age or older, including those not showing symptoms.
Pfizer/BioNTech’s coronavirus vaccine is 95% effective for preventing symptomatic illness.
A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.
Bamlanivimab is now authorized for nonhospitalized people at high risk for progressing to severe COVID-19.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
“The SalivaDirect test...is yet another testing innovation game changer that will reduce the demand for scarce testing resources.”
The nondrug is intended to improve the ability of children to pay attention, stay focused and control their behavior.
Tests like the one approved this week can show who is likely to be immune, but it’s not yet clear how long such immunity lasts.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.